Market research
EPZM Epizyme Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 247M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- 0.0%
- Beta
- -0.42
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US29428V1044
- Market cap
- 247M
- P/E ratio
- Not available
- Analyst target
- 6
- Dividend yield
- 0.0%
- Beta
- -0.42
About
About Epizyme Inc
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EPZM discussion.
5 years, 4 months ago
Epizyme, Inc is currently in a long term downtrend where the price is trading 25.6% below its 200 day moving average.
From a valuation standpoint, the stock is 95.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 60.3.
Epizyme, Inc's total revenue rose by 95.0% to $8M since the same quarter in the previous year.
Its net income has dropped by 17.4% to $-66M since the same quarter in the previous year.
Finally, its free cash flow fell by 49.8% to $-53M since the same quarter in the previous year.
Based on the above factors, Epizyme, Inc gets an overall score of 2/5.